EOS789, a broad-spectrum inhibitor of phosphate transport, is safe with an indication of efficacy in a phase 1b randomized crossover trial in hemodialysis patients
Open Access
- 30 October 2020
- journal article
- research article
- Published by Elsevier BV in Kidney International
- Vol. 99 (5), 1225-1233
- https://doi.org/10.1016/j.kint.2020.09.035
Abstract
No abstract availableFunding Information
- Chugai Pharmaceutical
This publication has 37 references indexed in Scilit:
- Oral calcium carbonate affects calcium but not phosphorus balance in stage 3–4 chronic kidney diseaseKidney International, 2013
- Differences Among Total and In Vitro Digestible Phosphorus Content of Plant Foods and BeveragesJournal of Renal Nutrition, 2012
- Differences among Total and In Vitro Digestible Phosphorus Content of Meat and Milk ProductsJournal of Renal Nutrition, 2012
- Daytime Rhythm and Treatment-Related Fluctuations of Serum Phosphorus Concentration in Dialysis PatientsAmerican Journal of Nephrology, 2012
- Mineral Metabolism Disorders in Chronic Kidney DiseaseJAMA, 2011
- Serum Levels of Phosphorus, Parathyroid Hormone, and Calcium and Risks of Death and Cardiovascular Disease in Individuals With Chronic Kidney DiseaseJAMA, 2011
- Vegetarian Compared with Meat Dietary Protein Source and Phosphorus Homeostasis in Chronic Kidney DiseaseClinical Journal of the American Society of Nephrology, 2011
- Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis populationNephrology Dialysis Transplantation, 2010
- Intestinal Npt2b Plays a Major Role in Phosphate Absorption and HomeostasisJournal of the American Society of Nephrology, 2009
- Mineral Metabolism, Mortality, and Morbidity in Maintenance HemodialysisJournal of the American Society of Nephrology, 2004